Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITROUS OXIDE, USP vs ENFLURANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.
Anesthesia induction and maintenance,Procedural sedation and analgesia,Off-label: labor analgesia, treatment of severe pain in emergency settings
Induction and maintenance of general anesthesia,Supplement to nitrous oxide and oxygen anesthesia
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.
Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination.
Terminal elimination half-life is approximately 4-8 hours in adults; context: prolonged with obesity due to high lipid solubility and storage in adipose tissue.
Nitrous oxide is metabolized minimally (approximately 0.004%) via intestinal bacterial reduction to free radicals and nitrogen. Pulmonary excretion unchanged accounts for >99% of elimination.
Primarily hepatic via cytochrome P450 (CYP2E1); approximately 2% undergoes oxidative metabolism to difluoromethoxy-difluoroacetic acid and fluoride ions; rest is excreted unchanged by lungs.
Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination.
Primarily eliminated by pulmonary excretion as unchanged drug (>90%); less than 5% is metabolized via CYP2E1 to fluoride ions and other metabolites, which are renally excreted.
<0.5% (minimally bound; essentially unbound in plasma).
Approximately 55-75% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
0.5–1.0 L/kg (rapid distribution to vessel-rich tissues; maintains rapid onset and offset).
Volume of distribution at steady state (Vdss) is approximately 3.5-4.5 L/kg, indicating extensive tissue distribution and lipid solubility.
Inhalation: 100% (administered as gas; absorbed directly across alveolar membrane).
Inhalation: Bioavailability is essentially 100% as administered via inhalation, with rapid absorption across the alveolar-capillary barrier.
No dose adjustment required; nitrous oxide is minimally excreted renally.
No specific GFR-based dose adjustment required; however, monitor for nephrotoxicity in severe renal impairment (e GFR <30 m L/min) due to potential fluoride ion accumulation.
No dose adjustment required; metabolism is minimal.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce concentration; Child-Pugh C: avoid due to risk of hepatotoxicity and altered metabolism.
Inhalation: 5-50% nitrous oxide in oxygen, titrated to effect; for anesthesia, up to 70%.
Induction: 1-4% inspired concentration; Maintenance: 0.5-2% inspired concentration; adjust based on age and response.
Decrease concentration and titrate slowly due to increased sensitivity; monitor for hypotension and hypoxia.
Reduce inspired concentration by 25-50% due to decreased minimal alveolar concentration (MAC) and increased sensitivity; monitor hemodynamics closely.
Nitrous oxide may cause megaloblastic anemia and neurological complications with prolonged use (e.g., >24 hours) due to inactivation of vitamin B12 and folate deficiency. Monitor for signs of B12 deficiency.
None
Risk of hypoxia due to diffusion hypoxia upon discontinuation; oxygen supplementation required. May cause bone marrow suppression, B12 deficiency neuropathy, and impaired vitamin B12-dependent enzyme activity. Use caution in patients with pre-existing neurological disease, hematologic disorders, or vitamin B12/folate deficiency. Chronic exposure can lead to reproductive toxicity and occupational hazard.
May cause dose-dependent respiratory and cardiovascular depression,Risk of seizures (especially with deep anesthesia or hypocarbia),Potential for hepatotoxicity (rare, but caution in patients with pre-existing liver disease),Malignant hyperthermia risk,Should not be used in patients with known sensitivity to halogenated anesthetics
Absolute: Known hypersensitivity, severe hematologic abnormalities (e.g., megaloblastic anemia), active vitamin B12 deficiency, need for prolonged oxygen therapy (e.g., pneumothorax, bowel obstruction), air trapping conditions (e.g., middle ear surgery, sinus infection). Relative: Pregnancy (first trimester), neurological disease, folate deficiency.
Known hypersensitivity to enflurane or other halogenated anesthetics,Known or suspected genetic susceptibility to malignant hyperthermia,Severe hypotension or hypovolemia (relative),Prior history of hepatitis after halothane or other halogenated agents (relative)
No specific food interactions. However, patients with vitamin B12 deficiency or those on methotrexate should ensure adequate B12 and folate intake; nitrous oxide can deplete B12 stores. Heavy meals before sedation may increase risk of aspiration and nausea.
No specific food interactions known for enflurane. Avoid alcohol for at least 24 hours post-anesthesia as it may increase sedation and hepatotoxicity risk.
Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data show no increased risk of major malformations with brief, low-dose exposure. Second/third trimesters: Use is generally considered safe for short durations; prolonged or repeated exposure may reduce uterine blood flow and cause fetal hypoxia. There is no evidence of increased congenital anomalies from routine use in dentistry or surgery.
Enflurane is not recommended during the first and second trimesters due to potential teratogenicity based on animal studies showing fetal malformations. During the third trimester, use is avoided for elective procedures as it may cause uterine relaxation and fetal depression. Risk is dose-dependent and duration-dependent.
Nitrous oxide is rapidly eliminated from plasma; low levels may pass into breast milk. No published M/P ratio. After a single dose, breastfeeding can be resumed once the mother is alert and has recovered from anesthesia. Limited data suggest no adverse effects on nursing infants. Caution with repeated or high doses.
Enflurane is excreted into breast milk in low concentrations. The M/P ratio is not well established but estimated around 0.5-1.0. Because of rapid clearance and minimal oral bioavailability, a single exposure is considered compatible with breastfeeding after waiting 24 hours. No adverse effects reported in infants.
No dose adjustments are typically required for short-term use. However, due to increased minute ventilation and decreased functional residual capacity in pregnancy, onset of action may be faster and depth of anesthesia may be greater. Consider using lower inspired concentrations (e.g., 30-50% N2O in O2) to avoid maternal hypoxia. Avoid prolonged exposure to reduce risk of fetal hypoxia and methemoglobinemia.
Pregnancy may decrease MAC (minimum alveolar concentration) by up to 40% due to progesterone and endogenous opioids. Dose should be reduced accordingly. No specific dose adjustment based on pharmacokinetic changes, but careful titration to effect is required.
Nitrous oxide has a rapid onset (30-60 seconds) and offset; monitor for diffusion hypoxia upon discontinuation by administering 100% oxygen for 3-5 minutes. Avoid in patients with pneumothorax, bowel obstruction, middle ear surgery, or intracranial air due to risk of expansion. Use with caution in patients with vitamin B12 deficiency or methylenetetrahydrofolate reductase (MTHFR) mutations due to inactivation of methionine synthase. Nitrous oxide is a potent analgesic but weak anesthetic; always combine with an amnestic agent (e.g., benzodiazepine) for procedural sedation. In pediatric patients, use 30-50% concentration; higher concentrations may cause vomiting or excitement. Check waste gas scavenging systems to prevent occupational exposure.
Enflurane is a potent inhalation anesthetic that can cause dose-dependent myocardial depression and hypotension. It sensitizes the myocardium to catecholamines, increasing arrhythmia risk. Enflurane may provoke seizure activity at high concentrations or with hypocapnia. Malignant hyperthermia trigger. Use caution in patients with hepatic or renal impairment due to fluoride ion release.
You may feel lightheaded, euphoric, or have tingling sensations; this is normal and will resolve quickly after stopping the gas.,You will receive oxygen after the procedure to prevent a sudden drop in oxygen levels.,Do not eat a heavy meal for 2-3 hours before sedation to reduce the risk of nausea or vomiting.,Inform your healthcare provider if you have a history of vitamin B12 deficiency, anemia, or lung problems (e.g., pneumothorax).,You should not drive, operate machinery, or make important decisions for 24 hours after sedation.
You will be unconscious and feel no pain during surgery.,You may experience nausea or shivering after waking up.,Inform your anesthesiologist if you have a personal or family history of malignant hyperthermia.,Avoid operating machinery or driving for at least 24 hours after anesthesia.,Report any unusual muscle stiffness, fever, or dark urine after surgery.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"Nitrous oxide, an NMDA receptor antagonist and anesthetic gas, can enhance the central nervous system (CNS) depressant effects of difenoxin, an opioid antidiarrheal that acts on mu-opioid receptors. This combination increases the risk of profound sedation, respiratory depression, and coma, particularly in elderly or debilitated patients. Concurrent use may also exacerbate hypotension and bradycardia due to synergistic effects on the autonomic nervous system."
"Nitrous oxide (N2O) is an NMDA receptor antagonist and can inhibit the enzyme methionine synthase, leading to decreased methionine and increased homocysteine levels. Lamotrigine, a sodium channel blocker and glutamate release inhibitor, has proconvulsant effects at high doses and can lower the seizure threshold. The combination may increase the risk of seizures and neurotoxicity, particularly in patients with underlying epilepsy or rapid dose escalation of lamotrigine."
"Enflurane, a halogenated volatile anesthetic, and venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), both inhibit neuronal reuptake of monoamines, leading to increased central nervous system (CNS) levels of serotonin and norepinephrine. Concurrent use may potentiate the risk of serotonin syndrome, characterized by agitation, hyperthermia, autonomic instability, and neuromuscular hyperactivity. Additionally, venlafaxine can lower the seizure threshold, while enflurane may produce epileptiform EEG activity, raising the potential for perioperative seizures."
"Enflurane is a halogenated volatile anesthetic that potentiates the effects of gamma-aminobutyric acid (GABA) at GABA-A receptors, leading to central nervous system (CNS) depression. Tiapride, a selective dopamine D2 receptor antagonist, can also cause CNS depression and prolong the QT interval. Combined use may result in additive CNS depression, increasing the risk of excessive sedation, respiratory depression, and hypotension. Additionally, both drugs can lower the seizure threshold, potentially increasing the risk of perioperative seizures."
"The combination of enflurane and levobupivacaine increases the risk of cardiotoxicity and central nervous system (CNS) toxicity. Enflurane sensitizes the myocardium to the arrhythmogenic effects of levobupivacaine, potentially leading to severe ventricular arrhythmias. Additionally, both drugs depress myocardial contractility and conduction, which may result in hypotension, bradycardia, or cardiac arrest."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITROUS OXIDE, USP vs ENFLURANE, answered by our medical review team.
NITROUS OXIDE, USP is a Inhalational Anesthetic that works by Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.. ENFLURANE is a Inhalational Anesthetic that works by Enflurane is a volatile halogenated ether that potentiates GABA-A receptor activity, inhibits NMDA receptors, and enhances glycine receptor function, leading to generalized central nervous system depression and anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITROUS OXIDE, USP and ENFLURANE depend on the specific clinical indication. These are both Inhalational Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITROUS OXIDE, USP is: Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.. The standard adult dose of ENFLURANE is: Induction: 0.5-4.5% inspired concentration; Maintenance: 0.5-3% inspired concentration with oxygen/nitrous oxide; via inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITROUS OXIDE, USP and ENFLURANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITROUS OXIDE, USP is classified as Category C. Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data sh. ENFLURANE is classified as Category C. Enflurane is not recommended during the first and second trimesters due to potential teratogenicity based on animal studies showing fetal malformations. During the third trimester,. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.